Related Experiment Video
Updated: Jul 12, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
[Effect of synthesized polypeptide (P16) on inhibiting cell transdifferentiation and fibrosis induced by connective
Wei Wang1, Yu-jun Shi, Li Zhang
1Key Laboratory of Transplant Engineering and Immunology, Ministry Of Health, West China Hospital, Sichuan University, Chengdu 610041, China.
Objective:
To explore the possibility of a CTGF originated hexadeca-peptide (named P16) to compete with the CTGF in binding integrin avP3 on rat tubular epithelial cells (NRK-52E) and inhibit the transdifferentiation and myofibroblasts of NRK-52E cells induced by CTGF.
Methods:
The NRK-52E cells were cultured in a condition with the existence of CTGF, P16-FITC (P16 labeled with fluorescein isothiocyanate), or both for 24h. The immunofluorescence staining and RT-PCR were employed to detect the expressions of the protein and mRNA of alpha-SMA and the collagen I and IV which indicate the cell trans-differentiation and fibrosis.
Results:
The P16 had stronger affinity with the NRK-52E cells than the CTGF. In a CTGF and P16 co-culture system, the P16 inhibited the expression of a-SMA, collagen I and IV up-regulated by the CTGF. However, P16 alone had no effect on cell trans-differentiation and fibrosis.
Conclusion:
The synthesized P16 is capable of binding with NRK-52E cells and inhibiting trans-differentiation and fibrosis of the NRK-52E cells induced by CTGF in vitro. This finding offers a possibility of developing a novel antifibrosis therapy that targets CTGF receptor.
Insights
A novel peptide, P16, binds strongly to rat kidney cells and inhibits connective tissue growth factor (CTGF)-induced fibrosis. This peptide shows potential for developing new antifibrosis therapies targeting CTGF receptors.
Area of Science:
- Cell Biology
- Biochemistry
- Renal Physiology
Background:
- Connective tissue growth factor (CTGF) plays a key role in promoting cell transdifferentiation and fibrosis.
- Integrin αvβ3 is a known receptor for CTGF on rat tubular epithelial cells (NRK-52E).
- Developing targeted therapies to inhibit CTGF-mediated fibrosis is a significant clinical need.
Purpose of the Study:
- To investigate a synthetic peptide (P16) derived from CTGF for its ability to compete with CTGF binding to integrin αvβ3.
- To evaluate the potential of P16 to inhibit CTGF-induced transdifferentiation and fibrosis in NRK-52E cells.
- To explore P16 as a potential therapeutic agent for antifibrosis treatments.
Main Methods:
- NRK-52E cells were cultured with CTGF, P16-FITC, or both.
- Immunofluorescence staining and RT-PCR were used to assess the expression of α-SMA and collagen I/IV.
- Cellular binding affinity of P16 and CTGF to NRK-52E cells was compared.
Main Results:
- P16 demonstrated a higher affinity for NRK-52E cells compared to CTGF.
- Co-culture with P16 significantly inhibited the upregulation of α-SMA, collagen I, and collagen IV induced by CTGF.
- P16 alone did not induce cell transdifferentiation or fibrosis.
Conclusions:
- The synthetic peptide P16 effectively binds to NRK-52E cells and inhibits CTGF-induced transdifferentiation and fibrosis in vitro.
- P16 shows promise as a therapeutic candidate for antifibrosis by targeting the CTGF receptor pathway.
- This study provides a foundation for developing novel antifibrosis therapies based on CTGF antagonism.
Related Concept Videos
TGF - β Signaling Pathway
Abnormal Proliferation
Forced Transdifferentiation
Artificial transdifferentiation occurs...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
